Physician profile
Susan E Neil
NPI 1225026826
$17,674.75
in general payments reported to CMS, 2019-2025
54 companies · $1,314 in 2025
The $1,314 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,886 · 2020: $3,034 · 2021: $3,657 · 2022: $3,114 · 2023: $1,972 · 2024: $1,699 · 2025: $1,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,976 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,976.23 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,533.96 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $2,230.95 | 2021-2025 | |
| Novo Nordisk INC | $1,663.58 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,104.47 | 2019-2025 | Evenity |
| Lilly USA, LLC | $1,066.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $940.70 | 2019-2025 | Trintellix |
| Esperion Therapeutics, INC. | $771.92 | 2020-2023 | Nexletol |
| Allergan, INC. | $744.48 | 2019-2021 | |
| Pfizer INC. | $677.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $608.35 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $487.81 | 2019-2022 | |
| Astellas Pharma US INC | $398.55 | 2019-2024 | Myrbetriq |
| Horizon Therapeutics Plc | $382.22 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $336.91 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $327.05 | 2019-2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Neil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.